LAVA Therapeutics NV — Director's Dealing 2025

Nov 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LAVA Therapeutics NV (LVTX)
CIK: 0001840748
Period of Report: 2025-11-13

Reporting Person: Backstrom Jay T. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-13	Share Options (Right to Buy)	$0.93	D	33390	Disposed	2035-02-12	Common Shares (33390)	Direct

Footnotes

F1: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.